Better Efficacy of Ramucirumab in Japanese Patients than in the Global Population with Unresectable Hepatocellular Carcinoma

Better Efficacy of Ramucirumab in Japanese Patients than in the Global Population with Unresectable Hepatocellular Carcinoma

Bibliographic Details
Main Author:	Masatoshi Kudo
Format:	Article
Language:	English
Published:	Karger Publishers 2020-05-01
Series:	Liver Cancer
Online Access:	https://www.karger.com/Article/FullText/507889

Similar Items

Impact of Multi-Drug Sequential Therapy on Survival in Patients with Unresectable Hepatocellular Carcinoma
by: Masatoshi Kudo
Published: (2021-01-01)

Potential of ramucirumab in treating hepatocellular carcinoma patients with elevated baseline alpha-fetoprotein
by: Gilabert M, et al.
Published: (2018-11-01)

Phase 1b study of galunisertib and ramucirumab in patients with advanced hepatocellular carcinoma
by: James J. Harding, et al.
Published: (2021-05-01)

Efficacy and Safety of Ramucirumab in Asian and Non-Asian Patients with Advanced Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Individual Data Analysis of Two Randomized Studies
by: Chia-Jui Yen, et al.
Published: (2020-05-01)

Ramucirumab, A Second-Line Option For Patients With Hepatocellular Carcinoma: A Review Of The Evidence
by: De Luca E, et al.
Published: (2020-05-01)

Cost-Effectiveness of Lenvatinib in the Treatment of Patients With Unresectable Hepatocellular Carcinomas in Japan: An Analysis Using Data From Japanese Patients in the REFLECT Trial
by: Azuma, M., et al.
Published: (2021)

Sorafenib for the treatment of unresectable hepatocellular carcinoma
by: Junji Furuse
Published: (2008-11-01)

Therapeutic efficacy of lenvatinib for patients with unresectable hepatocellular carcinoma based on the middle-term outcome.
by: Akira Fuchigami, et al.
Published: (2020-01-01)

Outcome of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma
by: Hadeel A Helmi, et al.
Published: (2020-01-01)

Efficacy And Safety Of Raltitrexed Plus Oxaliplatin-Based Transarterial Chemoembolization In Patients With Unresectable Hepatocellular Carcinoma
by: Shao W, et al.
Published: (2019-11-01)

Unresectable Ectopic Hepatocellular Carcinoma Treated with Sorafenib
by: Yi-Ling Ko, et al.
Published: (2020-04-01)

Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma
by: Mohamed A. Abd El Aziz, et al.
Published: (2020-10-01)

Baseline Liver Function and Subsequent Outcomes in the Phase 3 REFLECT Study of Patients with Unresectable Hepatocellular Carcinoma
by: Arndt Vogel, et al.
Published: (2021-07-01)

Conventional versus drug-eluting bead transarterial chemoembolization: A better option for treatment of unresectable hepatocellular carcinoma
by: Murtuza Razi, et al.
Published: (2021-02-01)

Ramucirumab for Patients with Intermediate-Stage Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Results from Two Phase 3 Studies (REACH and REACH-2)
by: Masatoshi Kudo, et al.
Published: (2021-07-01)

The Real-World Data in Japanese Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib from a Nationwide Multicenter Study
by: Kaoru Tsuchiya, et al.
Published: (2021-05-01)

Impact of Grip Strength in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib
by: Kei Endo, et al.
Published: (2020-08-01)

Hepatic arterial infusion chemotherapy for patients with huge unresectable hepatocellular carcinoma.
by: Wei-Lun Tsai, et al.
Published: (2014-01-01)

Unresectable hepatocellular carcinoma: new opportunities and prospects for therapy
by: Dzhamal T Abdurakhmanov, et al.
Published: (2019-06-01)

Y-90 microshperes in the treatment of unresectable hepatocellular carcinoma
by: Al-Kalbani Abdullah, et al.
Published: (2008-01-01)

Lenvatinib for the treatment of unresectable hepatocellular carcinoma: evidence to date
by: Personeni N, et al.
Published: (2019-01-01)

Efficacy of lenvatinib for unresectable hepatocellular carcinoma based on background liver disease etiology: multi-center retrospective study
by: Atsushi Hiraoka, et al.
Published: (2021-08-01)

Systemic Therapy for Hepatocellular Carcinoma: Latest Advances
by: Masatoshi Kudo
Published: (2018-10-01)

Efficacy and Safety of Lenvatinib Therapy for Unresectable Hepatocellular Carcinoma in a Real-World Practice in Korea
by: Myung Ji Goh, et al.
Published: (2021-01-01)

Efficacy and Safety of Transarterial Chemoembolization Combined With Anlotinib for Unresectable Hepatocellular Carcinoma: A Retrospective Study
by: Wenbo Guo MD, et al.
Published: (2020-10-01)

Efficacy and safety of selective internal radiation therapy with yttrium-90 for the treatment of unresectable hepatocellular carcinoma
by: Nguyen Van Thai, et al.
Published: (2021-05-01)

Lenvatinib as the key component of first-line therapy for patients with unresectable hepatocellular carcinoma
by: L. V. Bolotina
Published: (2020-11-01)

Clinical impact of lenvatinib in patients with unresectable hepatocellular carcinoma who received sorafenib
by: Yen-Yang Chen, et al.
Published: (2020-11-01)

Yttrium-90 resin microspheres as an adjunct to sorafenib in patients with unresectable hepatocellular carcinoma
by: Mahvash A, et al.
Published: (2016-02-01)

Radiation-Associated Lymphopenia and Outcomes of Patients with Unresectable Hepatocellular Carcinoma Treated with Radiotherapy
by: De B, et al.
Published: (2021-03-01)

A Paradigm Change in the Treatment Strategy for Hepatocellular Carcinoma
by: Masatoshi Kudo
Published: (2020-06-01)

Adjuvant Immunotherapy after Curative Treatment for Hepatocellular Carcinoma
by: Masatoshi Kudo
Published: (2021-09-01)

Real-Life Clinical Data of Cabozantinib for Unresectable Hepatocellular Carcinoma
by: Francesco Tovoli, et al.
Published: (2021-06-01)

Role of radiofrequency ablation in unresectable hepatocellular carcinoma: An Indian experience
by: Naveen Kalra, et al.
Published: (2013-04-01)

A Case of Advanced Hepatocellular Carcinoma with Partial Response after Continuous Ramucirumab Treatment beyond Radiological Progression
by: Yoshiyuki Wada, et al.
Published: (2020-04-01)

Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma
by: Breder, V., et al.
Published: (2022)

Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real‐world conditions—Multicenter analysis
by: Atsushi Hiraoka, et al.
Published: (2019-07-01)

Ramucirumab: Boon or bane
by: Priya Tiwari
Published: (2016-09-01)

Risk of HBV reactivation in patients with immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma
by: Ming-Huang Chen, et al.
Published: (2020-07-01)

Transarterial chemoembolization with pirarubicin-eluting microspheres in patients with unresectable hepatocellular carcinoma: Preliminary results
by: Mingjun Bai, et al.
Published: (2019-05-01)

Cannot write session to /tmp/vufind_sessions/sess_j5p526co3hdva8l5feropm4phl